Objective: To evaluate the HRU in a supplementary medicine environment in Brazil comparing intravenous (IV) treatments used in clinical practice. The health resources utilization (HRU) in lung cancer treatment is variable according to several items: the country where the treatment is performed, hospitalization, administration and drug costs. Methods: A total of 344 Lung cancer patients were selected within the records of a private hospital in Brazil. Of those, 69 patients that received pemetrexed or docetaxel as second line chemo. The chemotherapy protocols considered were: Pemetrexed 500mg/m2 every 3 weeks, Docetaxel 75mg/m2 every three weeks, Docetaxel 35mg/m2 weekly (3 times per cycle) and Docetaxel 40mg/m2 weekly (3 times per cycle). HRU frequency (hospitalization, clinical visits, complementary examinations, medication, transfusions) related to lung cancer treatment was reviewed retrospectively from clinical records. The costs were calculated in dolars (US$) following the original records for each cycle. The values for neutropenia were also calculated. Results: Pemetrexed 500mg/m2 every three weeks was used by 20.5% of the patients; Docetaxel 75 mg/m2 every three weeks by 17.1%; Docetaxel 35mg/m2 weekly (3 times per cycle) by 8,1% and Docetaxel 40mg/m2 weekly (3 times per cycle) by 1.1%.The cost of each cycle was U$6897.00 for Pemetrexed 500mg/m2; US$3041.00 for Docetaxel 75mg/m2; US$5919.00 for Docetaxel 35mg/m2 and US$6669.00 for Docetaxel 40mg/m2. The costs of neutropenia and febrile neutropenia episodes were respectively US$1310.00 and US$6000.00. Conclusion: Besides the cost of the drug is a mean point in health resources utilization we have to consider other variables to have a clear picture of each chemotherapy scheme costs and were the resources have been used. Since the chance of toxicity is different for every kind of treatment, all the inputs to reach the total cost of treatment are necessary.